Nasdaq Biotechnology Ishares ETF (IBB) Stock Price, Quote & News

Company Profile

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Phone: 1-800-474-2737

HScottMatusow Oct. 25 at 12:05 AM

It's actually kinda funny reading X and Stocktwit posts from bears on $QURE. If you going to attempt a bear case, stop using data from 2 years ago, use current data, and stop calling Gene Therapy "a drug." Thank you for playing! $XBI $IBB $IWM $SPY

0 · Reply

JFais Oct. 24 at 8:14 PM

Lot of names out there that friends are pitching me= heads win big/tails loss is limited (opportunity cost as the main risk) Glad to see that vs chasing binaries, but I am biased as the former = my type of setup $XBI $IBB

0 · Reply

Arthur86 Oct. 24 at 3:52 PM

$IBB $LABU $NEUP $BYND

0 · Reply

SwingPlayers Oct. 24 at 3:51 PM

Hmmm $NEUP dropped from $20+ to $5’s and then an insider buys 639,110 shares at $5.14 Guess why he did that? Because it still has a partnership with Merck for the MK-1167 drug in phase 2 trial in Alzheimer’s disease with $450M milestone payments. $LABU $IBB

1 · Reply

ajbski Oct. 24 at 1:44 PM

$NVAX Cantor Fitzgerald initiates coverage of Novavax with an Overweight rating and $18 Price Target. Oct. 24, 2025. 6:50 AM #Biotech #MatrixM #Nuvaxovid $IBB $XBI https://www.tipranks.com/news/the-fly/novavax-initiated-with-an-overweight-at-cantor-fitzgerald-thefly

0 · Reply

ajbski Oct. 23 at 3:22 PM

$NVAX HC Wainwright & Co. Raises Price Target to $11, Maintains Buy Rating | #Biotech #Novavax $IBB $XBI GuruFocus News 10/23/2025 09:34 https://www.gurufocus.com/news/3157581/nvax-hc-wainwright-co-raises-price-target-to-11-maintains-buy-rating-nvax-stock-news

0 · Reply

thinkandpick Oct. 23 at 8:01 AM

$PGNY $XLV $IBB $XBI $LABU Healthcare sector. Dirt-cheap Progyny (PGNY) with the fortress balance sheet announces another growth initiative effective January 2026, so there is no question that 2026 revenue will be higher than 2025 revenue: https://www.globenewswire.com/news-release/2025/10/22/3171210/0/en/Progyny-Expands-Global-Benefits-to-Include-Pregnancy-Postpartum-and-Menopause.html

0 · Reply

Its_Never_Too_Late Oct. 22 at 2:09 PM

$XBI $CAPR $IBB

1 · Reply

ajbski Oct. 22 at 7:57 AM

$NVAX Yuge! “Detection of Anti-SARS-CoV-2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID-19 Vaccine” First published: 21 October 2025 Journal of Medical Virology, Volume 97, Issue 10 e70645 $NVAX #Biotech $XBI $IBB http://onlinelibrary.wiley.com/doi/10.1002/jm… https://x.com/sandcastle_kat/status/1980899413573914914?s=46

0 · Reply

JFais Oct. 21 at 8:59 PM

Like these "calls for prudence" after a big year (vs overleveraged accounts YOLOing binaries) Expect this to be a multi-year upswing for biotech and want to see everyone do well $XBI $IBB But equally important to avoid giving gains back to the market

0 · Reply

Trade Tracker: Jason Snipe buys the IBB

Oct 6, 2025, 1:29 PM EDT - 18 days ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 1, 2025, 5:48 PM EDT - 23 days ago

‘Fast Money' traders talk opportunities in health care stocks

AMGN BIIB BMY LLY MRK MRNA PFE

Sep 9, 2025, 10:41 AM EDT - 6 weeks ago

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

XBI

Sep 3, 2025, 3:32 PM EDT - 7 weeks ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH BMRN CYTK XBI

Sep 1, 2025, 8:03 AM EDT - 7 weeks ago

BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH

Jul 16, 2025, 3:30 PM EDT - 3 months ago

Trump's deadline looms for Big Pharma companies facing new tariffs

XLV

Jul 13, 2025, 7:01 AM EDT - 3 months ago

Heard on the Street: Why pharma stocks have outperformed the broader market since Trump threatened the industry with a 200% tariff

XLV

Jul 9, 2025, 11:09 AM EDT - 3 months ago

Trump threatens 50% tariffs on copper, 200% on pharmaceuticals

CPER XBI

Jul 6, 2025, 11:12 AM EDT - 3 months ago

Biotech Looks Ready To Run, But ETFs, Which One? IBB Vs. XBI

XBI

Jul 5, 2025, 8:05 AM EDT - 4 months ago

5 Stocks I'm Buying As The 'Big Beautiful Bill' Pushes The Market To New Highs

ACHC AMH ARE CHAT COLD ELS FSLR

Jun 13, 2025, 6:20 PM EDT - 4 months ago

Fast Money: WTI, IBB, UBER, CAT

UBER CAT

May 30, 2025, 3:30 PM EDT - 5 months ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIB BIS

May 29, 2025, 10:59 AM EDT - 5 months ago

IBB: Now Is The Time To Be Contrarian

May 28, 2025, 12:22 PM EDT - 5 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD ILMN NVS SDGR

May 13, 2025, 1:43 PM EDT - 5 months ago

Trump is right about drug prices. He's just going about it all wrong.

XBI XLV

May 7, 2025, 11:13 AM EDT - 6 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA NVAX PFE GSK SRPT XBI

Apr 14, 2025, 2:03 PM EDT - 6 months ago

Trump Says Pharmaceutical Tariffs Coming in Near Future

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 11, 2025, 7:17 PM EDT - 7 months ago

Sell into strength in pharma, says Mizuho's Jared Holz

XBI

Apr 11, 2025, 10:30 AM EDT - 7 months ago

Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 11, 2025, 5:30 AM EDT - 7 months ago

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

XBI

Apr 9, 2025, 6:32 PM EDT - 7 months ago

BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 9, 2025, 2:27 PM EDT - 7 months ago

Explainer: Prescription drugs become a target in Trump's trade war

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 9, 2025, 1:06 PM EDT - 7 months ago

Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 9, 2025, 11:49 AM EDT - 7 months ago

Why drug stocks are no longer a safe haven from the stock market's turmoil

ABBV AMGN BMY JNJ LLY MRK PFE

Mar 2, 2025, 8:33 AM EST - 8 months ago

Invest In A New Biotech Bull Market With XBI And IBB

XBI

Feb 25, 2025, 11:06 AM EST - 8 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

XLV AGNG ARKG BBC BBH BBP BIB

Feb 3, 2025, 6:43 PM EST - 9 months ago

How tariffs could impact pharma and early-stage healthcare investments

XLV

Jan 30, 2025, 7:06 PM EST - 9 months ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH ELVN

Jan 13, 2025, 6:10 PM EST - 10 months ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Dec 10, 2024, 1:33 PM EST - 11 months ago

iShares Biotechnology ETF: Playing Defense

Nov 25, 2024, 6:44 PM EST - 11 months ago

Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation

HIMS LLY MRNA NVO PFE

Nov 25, 2024, 6:22 PM EST - 11 months ago

Health care stocks jump on Trump's nominee for FDA head

HIMS LFMD MRNA PFE

Nov 20, 2024, 6:21 PM EST - 1 year ago

Final Trade: Euro, IBB, SMH, NEM

SMH NEM

Nov 15, 2024, 6:54 PM EST - 1 year ago

Final Trade: West Pharma, Cameco, iShares Biotechnology ETF and Applied Digital Corp

APLD CCJ WST

Oct 14, 2024, 7:36 AM EDT - 1 year ago

IBB: A Near-20x P/E Is Historically Pricey, Technical Trends Neutral

Aug 30, 2024, 5:34 PM EDT - 1 year ago

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

GILD XBI

Aug 12, 2024, 4:25 PM EDT - 1 year ago

Biotech stocks will get a tailwind from rate cuts, says Stempoint's Michelle Ross

LLY XBI

Jul 30, 2024, 3:25 PM EDT - 1 year ago

Analyst is 'extremely bullish' on biopharma

MRK PFE

Jul 28, 2024, 12:25 PM EDT - 1 year ago

iShares Biotechnology ETF: Significant Upside Potential As Sector Gains Momentum

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

XBI

May 13, 2024, 9:00 AM EDT - 1 year ago

For Biotech Stocks To Move Higher, This Must Move Lower

XBI

Apr 10, 2024, 9:27 AM EDT - 1 year ago

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

AMGN ASND CYTK DXCM EW HRTS IHE

Apr 2, 2024, 4:56 PM EDT - 1 year ago

Biotech's Next Gold Rush: Weight-Loss Drugs

LLY NVO

Mar 28, 2024, 2:01 AM EDT - 1 year ago

Catch The Medical Breakthroughs With The IBB ETF

Mar 26, 2024, 4:46 AM EDT - 1 year ago

IBB: Let It Rest

Mar 9, 2024, 3:59 AM EST - 1 year ago

Why Biotech Stocks May Be Ready For A Recovery

BBH XLV

Feb 15, 2024, 1:44 PM EST - 1 year ago

Navigating the big run in biotech

XBI

HScottMatusow Oct. 25 at 12:05 AM

0 · Reply

JFais Oct. 24 at 8:14 PM

0 · Reply

Arthur86 Oct. 24 at 3:52 PM

$IBB $LABU $NEUP $BYND

0 · Reply

SwingPlayers Oct. 24 at 3:51 PM

1 · Reply

ajbski Oct. 24 at 1:44 PM

0 · Reply

ajbski Oct. 23 at 3:22 PM

0 · Reply

thinkandpick Oct. 23 at 8:01 AM

0 · Reply

Its_Never_Too_Late Oct. 22 at 2:09 PM

$XBI $CAPR $IBB

1 · Reply

ajbski Oct. 22 at 7:57 AM

0 · Reply

JFais Oct. 21 at 8:59 PM

0 · Reply

Night_Owl_Biotech Oct. 21 at 7:40 PM

$FOLD continues to trade at lower multiples of projected sales versus 3 peers with like dollar forecasts & gross margin profiles. FOLD is currently defending its patent rights against a generic pharma hoping to sell a biosimilar. We suspect this could be the reason why FOLD does not trade at like multiples versus its peers $MIRM $TARS $KNSA Again by peers we mean those commercial-stage bios with similar revenue projections & patent lives. This is not investment advice. $IBB

2 · Reply

Night_Owl_Biotech Oct. 21 at 5:34 PM

@outlawinvestor1 FYI $MRUS filed their 14D9 this morning that includes, among other things, the revenue forecast provided $GMAB as part of the broader financial projections. You were definitely right again. The MRUS forecasts, especially in the later years, are considerably higher than 3 analysts had projected. I prepared a simple comparison of the 2 showing you snapshots as well. We track these for all commercial-stage bios. It's our experience the projections are closer except for BPMC (BPMC's forecasts were much higher than analysts in the later years). I included an updated comparison of the various revenue multiples versus $PTGX as well. For those interested in clinical-stage bios (and commercial-stage for that matter), may I recommend you follow outlawinvestor1 Otherwise FYI only. This is not investment advice. $IBB $IBBQ

0 · Reply

sethmarcus Oct. 21 at 3:43 PM

Me gusta, me gusta mucho! Health Care sector trying for its best closing price since March, and has absolutely no stocks within the sector trading with a bearish RSI (30 or <) $PFE $XLV $SPY $IBB $LLY

0 · Reply

JFais Oct. 21 at 1:34 PM

$XBI $IBB Liked the terminology (have heard in other phrasing/words)

0 · Reply

bOr_15Cave Oct. 20 at 5:04 PM

$IBB biotech basket momentum. Entry 141.60, stop 138.90, PT 147.80. A push over 142.60 with 1.5 times 20D volume confirms. Good for staged adds while trailing risk.

0 · Reply

MessAndGetHorns Oct. 20 at 2:59 PM

$ESTA Where is the next resistance and new support? Love the price action. She has been on a tear and it's only just begun especially with the new tech they rolled out on their breast implants! $SPY $QQQ $IWM $IBB

2 · Reply

ZacksResearch Oct. 20 at 12:30 PM

Biotech’s back — and the rally looks real. 💥 $IBB, $ARKG, $SBIO, $BBC, and $BBP are soaring as Fed rate cut optimism, a wave of FDA approvals, fresh deals, and lower valuations spark major momentum across the sector. Find out what’s fueling biotech’s 2025 comeback 👉 https://www.zacks.com/stock/news/2772024/biotech-etfs-bounce-back-in-2025-heres-why?cid=sm-stocktwits-2-2772024-teaser-16718&ADID=SYND_STOCKTWITS_TWEET_2_2772024_TEASER_16718

0 · Reply

ZacksResearch Oct. 20 at 10:53 AM

Biotech boom: $IBB soars 30.2% in six months! 🚀 📊 Still undervalued with a forward P/E of 19.66X vs. the S&P 500 at 20.13X 💸 Fed's rate cuts offer cheaper funding, boosting growth potential 💊 Recent FDA approvals and strategic pharma deals add momentum Explore the full biotech rally story here 👉 https://www.zacks.com/stock/news/2772024/biotech-etfs-bounce-back-in-2025-heres-why?cid=sm-stocktwits-2-2772024-body-16720&ADID=SYND_STOCKTWITS_TWEET_2_2772024_BODY_16720

0 · Reply

QuantLake Oct. 19 at 8:21 PM

Gold Peaks, Crypto Slides Based on 3-month ROC rankings, the VanEck Gold Miners ETF $GDX rose to 54.0%, within the top decile of the past year. The iShares Biotechnology ETF $IBB and iShares Global Clean Energy ETF $ICLN followed near their yearly highs at 18.9% and 21.7%. While $GDX accelerated, the iShares Bitcoin Trust $IBIT dropped to -9.3%, near the 17th percentile. Infrastructure steadied, but real estate $VNQ stayed weak, barely above zero. Commodities and innovation hold momentum, while yield and property remain subdued.

0 · Reply

ajbski Oct. 19 at 7:12 PM

$NVAX On October 13, 2025, SHAH CAPITAL MANAGEMENT added 300,000 shares of Novavax Inc at a trade price of $8.62 per share, marking a 2.61% increase in its position. VERY BULLISH SIGN FOR $NVAX #Biotech $IBB $XBI https://www.gurufocus.com/news/3149093/shah-capital-management-increases-stake-in-novavax-inc

0 · Reply

FairValTrading Oct. 19 at 1:21 AM

$DNA $XBI $IBB $ARK.X

0 · Reply

FairValTrading Oct. 18 at 6:30 PM

might needs a push into $20S to stop the nonsense $16S ➡️ $13 🔜 16 rides. Co. well aligned with the #pharma #biotech insourcing and carries #transformational one if kind #IP. $XBI $IBB $ARK.X

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	552,023
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A